Caffeine content of decaffeinated coffee

Journal of Analytical Toxicology

Volumn 30, Issue 8, 2006, Pages 611-613

  McCusker, Rachel R ^a   Fuehrlein, Brian ^a   Goldberger, Bruce A ^a   Gold, Mark S ^a   Cone, Edward J ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b ConeChem Research LLC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE;

ARTICLE; COFFEE; FOOD INTAKE; TREATMENT CONTRAINDICATION;

EID: 33750177598     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/30.8.611     Document Type: Article

References (14)

1. D.M. Graham. Caffeine - its identity, dietary sources, intake and biological effects. Nutr. Rev. 36: 97-102 (1978).
2. G. Tanda and S.R. Goldberg. Alteration of the behavioral effects of nicotine by chronic caffeine exposure. Pharmacol. Biochem. Behav. 66: 47-64 (2000).
3. FDA/National Consumers League-Pamphlet on Food and Drug Interactions, 1998; http://vm.cfsan.fda.gov/~lrd/fdinter.html (accessed July 2004).
4. F.A. Belibi, D.P. Wallace, T. Yamaguchi, M. Christensen, G. Reif, and J.J. Grantham. The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 13: 2723-2729 (2002).
5. R.R. McCusker, B.A. Goldberger, and E.J. Cone. Caffeine content of specialty coffees. J. Anal. Toxicol. 27: 520-522 (2003).
6. R.R. McCusker, B.A. Goldberger, and E.J. Cone. Caffeine content of energy drinks, carbonated sodas, and other beverages. J. Anal. Toxicol. 30: 112-114 (2006).
7. J.A. Carrillo and J. Benitez. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin. Pharmacokinet. 39: 127-153 (2000).
8. R.R. Griffiths, G.E. Bigelow, I.A. Liebson, M. O'Keefe, D. O'Leary, and N. Russ. Human coffee drinking: manipulation of concentration and caffeine dose. J. Exp. Anal. Behav. 45: 133-148 (1986).
9. R.R. Griffiths, G.E. Bigelow, and I.A. Liebson. Reinforcing effects of caffeine in coffee and capsules. J. Exp. Anal. Behav. 52: 127-140 (1989).
10. R.R. Griffiths, S.M. Evans, S.J. Heishman, K.L. Preston, C.A. Sannerud, B. Wolf, and P.P. Woodson. Low-dose caffeine discrimination in humans. J. Pharmacol. Exp. Ther. 252: 970-978 (1990).
11. J.R. Hughes, W.K. Hunt, S.T. Higgins, W.K. Bickel, J.W. Fenwick, and S.L. Pepper. Effect of dose on the ability of caffeine to serve as a reinforcer in humans. Behav. Pharmacol. 3: 211-218 (1992).
12. R.R. Griffiths, G.E. Bigelow, and I.A. Liebson. Human coffee drinking: reinforcing and physical dependence producing effects of caffeine. J. Pharmacol. Exp. Ther. 239: 416-425 (1986).
13. S.M. Evans and R.R. Griffiths. Caffeine withdrawal: a parametric analysis of caffeine dosing conditions. J. Pharmacol. Exp. Ther. 289: 285-294 (1999).
14. J.H. Boublik, M.J. Quinn, J.A. Clements, A.C. Herington, K.N. Wynne, and J.W. Funder. Coffee contains potent opiate receptor binding activity. Nature 301: 246-248 (1983).